Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051896 | 0.87 | SCD (0.47) | PRMT5AURKAPDE5APDE4APDE4B | |
| SCHEMBL4057922 | 0.86 | AURKA (0.48) | PRMT5AURKAPDE5APDE4APDE4B | |
| SCHEMBL4051426 | 0.86 | AURKA (0.42) | PRMT5AURKAPDE5APDE4APDE4B | |
| SCHEMBL4062368 | 0.86 | PRMT5 (0.45) | PRMT5AURKAUSP30TBK1NOS3 | |
| SCHEMBL13608306 | 0.83 | HDAC6 (0.41) | — | |
| SCHEMBL4063060 | 0.83 | DHODH (0.53) | PRMT5AURKATBK1CYP3A4NOS3 | |
| SCHEMBL4055330 | 0.82 | AURKA (0.67) | AURKATBK1NOS3NOS1NOS2 | |
| SCHEMBL4059595 | 0.81 | TP53 (0.56) | PRMT5AURKATBK1NOS3NOS1 | |
| SCHEMBL4053057 | 0.79 | AURKA (0.50) | AURKATBK1NOS3NOS1NOS2 | |
| SCHEMBL4058280 | 0.79 | AURKA (0.50) | AURKATBK1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | PRMT5 752/4885AURKA 247/4885PDE5A 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.